BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Graves Ophthalmopathy Market – Forecast to 2030,’ thoroughly examines the Graves Ophthalmopathy industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Phenylketonuria Treatment Market – Forecast to 2030,’ thoroughly examines the Phenylketonuria Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Postsurgical Pain Market – Forecast to 2030,’ thoroughly examines the Postsurgical Pain industry to provide essential data & information for the targeted readers.

Galapagos NV (Euronext & NASDAQ: GLPG) will present data at the United European Gastroenterology(UEG)Week2022,taking place from8-11 October 2022. Several Galapagos driven presentationswill be showcased, including new post hoc analyses of the SELECTION study, which investigated the safety and efficacy of Jyseleca®(filgotinib).

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022.

Rhythm Pharmaceuticals, Inc. announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company’s Executive Leadership Team, effective September 26, 2022.

Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2022 following the close of market on Thursday, November 3, 2022.

Teva Pharmaceutical Industries Ltd. announced that it will issue a press release on its third quarter 2022 financial results on Thursday, November 3, 2022 at 7:00 a.m. ET.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”,) announced today the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11446428) titled, “Cleaning Method for Prepless Colonoscopy.”

Sorrento Therapeutics, Inc. announced that Dr. Mike A. Royal, Chief Medical Officer, will participate in an upcoming Key Opinion Leader Panel Discussion that will focus on the great unmet need in non-small cell lung cancer and the potential of abivertinib, a novel, third-generation, EGFR/BTK inhibitor.